MolecularMD was founded to address the critical needs of chronic myelogenous leukemia (CML) patients. Investigators at Oregon Health Science University (OHSU) revealed that these patients often develop a wide range of genetic aberrations during the progression of their disease. They require accurate and reliable molecular diagnosis to determine the recommended therapeutic course of action. Moreover, highly accurate and reproducible molecular monitoring of residual disease in CML patients is critical for reliable assessment of current therapy efficacy.
Our efforts are geared toward improving cancer patient survival by linking molecular response to effective molecular cancer therapy. As such, we provide testing services for the clinical development of targeted cancer therapies. Our ultimate goal is to become the leader in targeted molecular assays for oncodiagnostics and, eventually, for all of personalized medicine.